Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease.
Monath TP, Nichols R, Feldmann F, Griffin A, Haddock E, Callison J, Meade-White K, Okumura A, Lovaglio J, Hanley PW, Clancy CS, Shaia C, Rida W, Fusco J. Monath TP, et al. Among authors: nichols r. Front Immunol. 2023 Sep 4;14:1216225. doi: 10.3389/fimmu.2023.1216225. eCollection 2023. Front Immunol. 2023. PMID: 37731485 Free PMC article.
Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential.
Monath TP, Nichols R, Tussey L, Scappaticci K, Pullano TG, Whiteman MD, Vasilakis N, Rossi SL, Campos RK, Azar SR, Spratt HM, Seaton BL, Archambault WT, Costecalde YV, Moore EH, Hawks RJ, Fusco J. Monath TP, et al. Among authors: nichols r. PLoS Pathog. 2022 Jun 27;18(6):e1010658. doi: 10.1371/journal.ppat.1010658. eCollection 2022 Jun. PLoS Pathog. 2022. PMID: 35759511 Free PMC article.
High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission.
Morozov I, Monath TP, Meekins DA, Trujillo JD, Sunwoo SY, Urbaniak K, Kim IJ, Narayanan SK, Indran SV, Ma W, Wilson WC, O'Connor C, Dubey S, Troth SP, Coller BA, Nichols R, Martin BK, Feldmann H, Richt JA. Morozov I, et al. Among authors: nichols r. Emerg Microbes Infect. 2021 Dec;10(1):651-663. doi: 10.1080/22221751.2021.1903343. Emerg Microbes Infect. 2021. PMID: 33719915 Free PMC article.
rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.
Monath TP, Fast PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, Nichols R, Heppner DG, Simon JK, Dubey S, Troth SP, Wolf J, Singh V, Coller BA, Robertson JS; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Monath TP, et al. Among authors: nichols r. Vaccine X. 2019 Jan 29;1:100009. doi: 10.1016/j.jvacx.2019.100009. eCollection 2019 Apr 11. Vaccine X. 2019. PMID: 31384731 Free PMC article.
A live, attenuated recombinant West Nile virus vaccine.
Monath TP, Liu J, Kanesa-Thasan N, Myers GA, Nichols R, Deary A, McCarthy K, Johnson C, Ermak T, Shin S, Arroyo J, Guirakhoo F, Kennedy JS, Ennis FA, Green S, Bedford P. Monath TP, et al. Among authors: nichols r. Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6694-9. doi: 10.1073/pnas.0601932103. Epub 2006 Apr 14. Proc Natl Acad Sci U S A. 2006. PMID: 16617103 Free PMC article. Clinical Trial.
ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense.
Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, Liu J, Gardner B, Downing G, Blum PS, Kemp T, Nichols R, Weltzin R. Monath TP, et al. Among authors: nichols r. Int J Infect Dis. 2004 Oct;8 Suppl 2:S31-44. doi: 10.1016/j.ijid.2004.09.002. Int J Infect Dis. 2004. PMID: 15491873 Free PMC article. Review.
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P. Monath TP, et al. Among authors: nichols r. J Infect Dis. 2003 Oct 15;188(8):1213-30. doi: 10.1086/378356. Epub 2003 Oct 3. J Infect Dis. 2003. PMID: 14551893 Clinical Trial.
1,268 results